$0.32
-0.01 (-3.89%)
Open$0.33
Previous Close$0.33
Day High$0.34
Day Low$0.32
52W High$1.57
52W Low$0.32
Volume—
Avg Volume748.8K
Market Cap11.73M
P/E Ratio—
EPS$-0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,071.3% upside
Current
$0.32
$0.32
Target
$3.76
$3.76
$2.62
$3.76 avg
$5.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.23M | 7.84M | 7.68M |
| Net Income | -32,398,401 | -2,005,672 | -1,738,578 |
| Profit Margin | -619.8% | -25.6% | -22.6% |
| EBITDA | -32,970,613 | -2,263,216 | -2,551,790 |
| Free Cash Flow | — | -1,406,564 | -1,071,377 |
| Rev Growth | — | +12.8% | +0.1% |
| Debt/Equity | 0.06 | 0.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |